Press Releases

Releases inaugural report less than one year after becoming a publicly-traded company, demonstrating its strong commitment to ESG stewardship Announces new long-term commitments focused on net-zero greenhouse gas emissions, workforce diversity and philanthropy SALT LAKE CITY, March 24, 2022 /

Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in gastrointestinal oncology and to advance up to 40 novel potential medicines Expanded our collaboration with Bayer to include the use of Recursion's OS to

Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored clinical trial for cerebral cavernous malformation (CCM) CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5 SALT LAKE

SALT LAKE CITY, March 3, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX) today provided updated guidance on clinical trial starts: Recursion's leadership team has decided that conducting a dose optimization study in a sheep efficacy model of Tay-Sachs disease is prudent and in the best interest

SALT LAKE CITY, March 2, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences: KeyBanc Capital Markets Emerging Technology

SALT LAKE CITY, Feb. 8, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences: SVB Leerink 11th Annual Global Healthcare

The deal, worth several billion dollars, is a future-looking model of technology-enabled target and drug discovery SALT LAKE CITY, Dec. 7, 2021 / PRNewswire / --  Recursion  (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug

Use of latest Recursion inference technologies to expand exploration of fibrosis and may extend the collaboration to more than a dozen programs in total Recursion's powerful inferential search capabilities leverage more than 100 million prior experiments conducted in Recursion's automated

Appointments will support continued expansion in neuroscience and acceleration of inferential search capabilities Tim Ahfeldt, Ph.D., Irit Rappley, Ph.D. and Glenn Morrison, Ph.D. to bolster neuroscience research and clinical development SALT LAKE CITY, Nov.

- Received Fast Track Designation for REC-2282, a potential treatment for NF2 meningiomas, and expect to enroll the first patient in a Phase 2/3 trial in early 2022 - Advanced REC-994, a potential treatment for CCM, and now expect to enroll the first patient in a phase 2 trial in early 2022 -